(NASDAQ: VALN) Valneva Se's forecast annual revenue growth rate of 30.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Valneva Se's revenue in 2024 is $167,079,347.On average, 3 Wall Street analysts forecast VALN's revenue for 2024 to be $32,033,973,418, with the lowest VALN revenue forecast at $27,372,637,581, and the highest VALN revenue forecast at $41,272,186,510. On average, 3 Wall Street analysts forecast VALN's revenue for 2025 to be $35,884,617,994, with the lowest VALN revenue forecast at $34,200,169,360, and the highest VALN revenue forecast at $37,156,219,742.
In 2026, VALN is forecast to generate $53,827,065,904 in revenue, with the lowest revenue forecast at $47,250,965,101 and the highest revenue forecast at $59,835,016,045.